Last reviewed · How we verify
SPL026
At a glance
| Generic name | SPL026 |
|---|---|
| Also known as | DMT, dimethyltryptamine, n,n-dimethytryptaimine, N,N-dimethyltryptamine |
| Sponsor | Small Pharma Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- SPL026 With or Without SSRIs in Participants With MDD (PHASE1)
- SPL026 (DMT Fumarate) in Healthy Subjects and MDD Patients (PHASE1, PHASE2)
- IM and IV SPL026 Drug Product in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SPL026 CI brief — competitive landscape report
- SPL026 updates RSS · CI watch RSS
- Small Pharma Ltd portfolio CI